BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led the...
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

Luminary, Case Western partner on CAR T against BLyS  Minneapolis-based Luminary Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS target for use in CAR T constructs; financial...
BioCentury | Jul 2, 2020
Finance

CRISPR, Acceleron follow-ons among year’s largest

A pair of biotechs priced upsized follow-on offerings late Tuesday, with CRISPR Therapeutics and Acceleron each raising $450 million, good for a tie for the year’s tenth-largest follow-on financing. CRISPR Therapeutics AG (NASDAQ:CRSP) sold 6.4...
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

A recommendation by EMA’s CHMP suggests remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) could soon gain a speedy conditional approval to treat COVID-19. The committee announced the decision this week along with a basket of other...
BioCentury | Jun 24, 2020
Finance

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce...
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...
Items per page:
1 - 10 of 6832
BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led the...
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

Luminary, Case Western partner on CAR T against BLyS  Minneapolis-based Luminary Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS target for use in CAR T constructs; financial...
BioCentury | Jul 2, 2020
Finance

CRISPR, Acceleron follow-ons among year’s largest

A pair of biotechs priced upsized follow-on offerings late Tuesday, with CRISPR Therapeutics and Acceleron each raising $450 million, good for a tie for the year’s tenth-largest follow-on financing. CRISPR Therapeutics AG (NASDAQ:CRSP) sold 6.4...
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

A recommendation by EMA’s CHMP suggests remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) could soon gain a speedy conditional approval to treat COVID-19. The committee announced the decision this week along with a basket of other...
BioCentury | Jun 24, 2020
Finance

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce...
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...
Items per page:
1 - 10 of 6832